Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 390, Issue 9, 2017, Pages 939-948

  Wetzl, Veronika ^a,b   Schinner, Elisabeth ^a   Kees, Frieder ^a   Faerber, Lothar ^a,b   Schlossmann, Jens ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

cGMP dependent protein kinase; Interstitial fibrosis; Kidney; Phosphodiesterase 5 inhibitor; Serelaxin; Signaling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGEN 1A1; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; FIBRONECTIN; GELATINASE; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SERELAXIN; UNCLASSIFIED DRUG; ZAPRINAST; PHOSPHODIESTERASE V INHIBITOR; PURINE DERIVATIVE; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; KIDNEY FIBROSIS; KIDNEY TISSUE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; WILD TYPE; ANIMAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECT; FIBROSIS; GENETICS; KIDNEY; KIDNEY DISEASE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DRUG THERAPY, COMBINATION; FIBROSIS; KIDNEY; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; PHOSPHODIESTERASE 5 INHIBITORS; PURINONES; RECOMBINANT PROTEINS; RELAXIN; SIGNAL TRANSDUCTION; URETERAL OBSTRUCTION;

EID: 85025120448     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-017-1394-z     Document Type: Article

References (36)

1. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ (2013) Relaxin family peptides and their receptors. Physiol Rev 93:405–480. doi:10.1152/physrev.00001.2012
2. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520. doi:10.1124/pr.58.3.5
3. Buglioni A, Burnett JC Jr (2016) New pharmacological strategies to increase cGMP. Annu Rev Med 67:229–243. doi:10.1146/annurev-med-052914-091923
4. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A (2002) CTGF expression in mesangial cells: involvement of SMADs MAP kinase, and PKC. Kidney Int 62:1149–1159. doi:10.1111/j.1523-1755.2002.kid567.x
5. Chevalier RL, Forbes MS, Thornhill BA (2009) Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75:1145–1152. doi:10.1038/ki.2009.86
6. Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS (2012) Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoSOne 7:e42714. doi:10.1371/journal.pone.0042714
7. Cui W et al (2014) Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Am J Physiol Renal Physiol 306:F996–1007. doi:10.1152/ajprenal.00657.2013
8. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S (2005) Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 53:895–903. doi:10.1369/jhc.5A6625.2005
9. Francis SH, Corbin JD (1994) Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol 56:237–272. doi:10.1146/annurev.ph.56.030194.001321
10. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1–52
11. Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 7:193–203. doi:10.1242/dmm.012062
12. Guan Z, Miller SB, Greenwald JE (1995) Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int 47:1569–1575. doi:10.1038/ki.1995.220
13. Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev 67:389–440. doi:10.1124/pr.114.009472
14. Hohenstein B, Daniel C, Wittmann S, Hugo C (2008) PDE-5 inhibition impedes TSP-1 expression, TGF-β activation and matrix accumulation in experimental glomerulonephritis. Nephrology Dialysis Transplantation 23:3427–3436. doi:10.1093/ndt/gfn319
15. Ibrahim MA, Satoh N, Ueda S (2003) Possible impact of nitric oxide on the antihypertensive effect of captopril and zaprinast. Adv Ther 20:143–148. doi:10.1007/BF02850201
16. Kiss T et al (2014) Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines MAP kinases and Akt. PLoS One 9:e104890. doi:10.1371/journal.pone.0104890
17. Kulkarni SK, Patil CS (2004) Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 26:789–799. doi:10.1358/mf.2004.26.10.872561
18. López-De León A, Rojkind M (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. Journal of Histochemistry & Cytochemistry 33:737–743. doi:10.1177/33.8.2410480
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
20. Metra M et al (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61:196–206. doi:10.1016/j.jacc.2012.11.005
21. Neild GH (2016) Life expectancy with chronic kidney disease: an educational review. Pediatr Nephrol:1–6. doi:10.1007/s00467-016-3383-8
22. Novartis (2017) provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure. Novartis International AG. https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart. Accessed 22 March 2017
23. Samuel CS (2005) Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 3:241–249. doi:10.3121/cmr.3.4.241
24. Schinner E, Schramm A, Kees F, Hofmann F, Schlossmann J (2013) The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis. Kidney Int 84:1198–1206. doi:10.1038/ki.2013.219
25. Schinner E, Wetzl V, Schlossmann J (2015) Cyclic nucleotide signalling in kidney fibrosis. Int J Mol Sci 16:2320–2351. doi:10.3390/ijms16022320
26. Schlossmann J, Schinner E (2012) cGMP becomes a drug target Naunyn Schmiedebergs. Arch Pharmacol 385:243–252. doi:10.1007/s00210-012-0730-6
27. Schramm A, Schinner E, Huettner JP, Kees F, Tauber P, Hofmann F, Schlossmann J (2014) Function of cGMP-dependent protein kinase II in volume load-induced diuresis. Pflugers Arch 466:2009–2018. doi:10.1007/s00424-014-1445-y
28. Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553–15558. doi:10.1074/jbc.273.25.15553
29. Sun XZ, Li ZF, Liu Y, Fang P, Li MX (2010) Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. Clin Exp Pharmacol Physiol 37:362–367. doi:10.1111/j.1440-1681.2009.05304.x
30. Takimoto E et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214–222. doi:10.1038/nm1175
31. Teerlink JR et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39. doi:10.1016/S0140-6736(12)61855-8
32. Wang Y et al (2006) Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 290:F167–F176. doi:10.1152/ajprenal.00197.2005
33. Wang X, Ward CJ, Harris PC, Torres VE (2010) Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77:129–140. doi:10.1038/ki.2009.438
34. Weber S et al (2007) Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ Res 101:1096–1103. doi:10.1161/CIRCRESAHA.107.154351
35. Wetzl V, Schinner E, Kees F, Hofmann F, Faerber L, Schlossmann J (2016) Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin. Front Pharmacol 7:195. doi:10.3389/fphar.2016.00195
36. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176. doi:10.1101/gad.14.2.163